美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

減肥藥

1,289.82

+40.123.21%

漲家數：5

跌家數：2

平家數：- -

市盈率：- -

高：1,301.32

開：1,249.67

低：1,249.67

收：1,249.70

資料載入中...

輝瑞依靠削減成本抵消收入下降的影響

輝瑞季度銷售額不及預期，COVID 治療收入下降

諾和諾德4月28日成交額為3.93億美元

安進4月28日成交額為5.89億美元

歐股“十一羅漢”收盤播報｜諾和諾德收漲將近2.7%，阿斯麥則跌超0.7%

Viking Therapeutics, Inc.盤中異動急速上漲5.04%

諾和諾德肥胖症藥物 Wegovy 首次在泰國上市

諾納生物合作伙伴輝瑞在2025 AACR年會上公佈基於TOP1i靶向人間皮素ADC療法的臨牀前數據

安進宣佈投資9億美元擴建俄亥俄州生產基地，新增350個工作崗位

安進擬斥9億美元擴建美國俄亥俄州工廠

數百億美元！艾伯維、默沙東、安進紛紛宣佈投資美國

輝瑞4月25日成交額為8.20億美元

諾和諾德4月25日成交額為4.83億美元

安進4月25日成交額為5.59億美元

禮來盤中異動股價大漲3.00%報885.49美元

諾和諾德贏得重大法律勝利，眾多Wegovy和Ozempic的調配版藥物被禁售

禮來公司請求歐洲藥品管理局重新審查阿爾茨海默氏症藥物建議

諾和諾德贏得重大法律勝利：多款司美格魯肽和諾和泰的配製版藥物被禁售

Viking Therapeutics, Inc.盤中異動早盤大幅下挫5.03%報24.37美元

諾和諾德盤中異動早盤快速下挫2.92%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4599/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"減肥藥","latestPrice":1289.8245,"timestamp":1746215999999,"preClose":1249.7039,"halted":0,"volume":72581789,"delay":0,"changeRate":0.032104,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":40.120605,"latestTime":"05-02 16:00:00 EDT","open":1249.6709,"high":1301.315,"low":1249.6709,"amount":8269919435.403536,"amplitude":0.041325,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1746230400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":10.663316,"peRate":37.494675,"turnoverRate":0.006871,"increases":5,"decrements":2,"flats":0,"marketCap":1381836112544,"floatMarketCap":1292379014240},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1301.315,"amplitude":0.041325,"preClose":1249.7039,"low":1249.6709,"pbRate":"10.663316","latestPrice":1289.8245,"volume":72581789,"delay":0,"open":1249.6709,"prevYearClose":1305.0607,"prevWeekClose":1313.4298,"prevMonthClose":1353.2255,"prevQuarterClose":1314.3724,"fiveDayClose":1313.4298,"twentyDayClose":1265.6132,"sixtyDayClose":1394.0055,"secType":"PLATE","market":"US","turnoverRate":0.006871,"peRate":37.494675,"marketCap":1381836112544,"floatMarketCap":1292379014240,"timestamp":1746215999999,"nameCN":"減肥藥"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":5,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531785467","title":"輝瑞依靠削減成本抵消收入下降的影響","url":"https://stock-news.laohu8.com/highlight/detail?id=2531785467","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531785467?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924425,"startTime":"0","endTime":"0","summary":"更新版 6-辉瑞依靠削减成本抵消收入下降的影响辉瑞公布喜忧参半的第一季度业绩，维持全年预期 COVID 疫苗销售好于预期，而抗病毒治疗销售下降预计到 2027 年底可节省 77 亿美元成本 第 8-9 段增加了首席执行官访谈中关于关税的评论Bhanvi Satija/Michael Erman. 路透4月29日 - 辉瑞PFE.N周二表示，公司将通过削减生产和研究业务的成本再节约17亿美元，尽管由于其COVID-19治疗药物Paxlovid的销售下降导致第一季度收入减少，但辉瑞仍强调了其运营效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R7108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4588","LU0122379950.USD","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","LU1023059063.AUD","LU0058720904.USD","BK4592","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2531378394","title":"輝瑞季度銷售額不及預期，COVID 治療收入下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2531378394","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531378394?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 18:49","pubTimestamp":1745923795,"startTime":"0","endTime":"0","summary":"辉瑞季度销售额不及预期，COVID 治疗收入下降路透4月29日 - 美国制药商辉瑞PFE.N周二公布的第一季度收入低于华尔街预期，受其COVID抗病毒治疗药物Paxlovid销售下滑的影响。 LSEG的数据显示，该公司第一季度总营收为137.0亿美元，而分析师预期为139.1亿美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R70Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","BK4599","BK4534","BK4581","BK4592","LU0234572021.USD","LU1057294990.SGD","BK4585","PFE","BK4533","IE00BLSP4239.USD","SG9999002232.USD","LU1883839398.USD","SG9999013999.USD","LU1066051498.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0306807586.USD","LU0058720904.USD","LU0225284248.USD","LU0321505868.SGD","SG9999011175.SGD","LU0225771236.USD","IE0002270589.USD","LU1894683264.USD","IE00BLSP4452.SGD","BK4568","BK4007","IE00B19Z3581.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU0306806265.USD","LU0122379950.USD","LU1066053197.SGD","SG9999003800.SGD","SG9999001176.SGD","LU0289739699.SGD","LU0868494617.USD","LU1894683348.USD","SG9999001176.USD","SGXZ57979304.SGD","LU0321505439.SGD","SG9999002224.SGD","LU0985481810.HKD","BK4588","LU0170899867.USD","BK4550"],"gpt_icon":0},{"id":"2531212892","title":"諾和諾德4月28日成交額為3.93億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531212892","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531212892?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 10:13","pubTimestamp":1745892796,"startTime":"0","endTime":"0","summary":"美东时间2025年4月28日，诺和诺德成交额为3.93亿美元，成交额较昨日减少18.75%，当日成交量为628.03万股。诺和诺德于2025年4月28日涨0.87%，报62.62美元，该股过去5个交易日涨7.35%，年初至今跌26.22%，过去60日跌25.63%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429101317a46b510f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429101317a46b510f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4585","LU0154236417.USD","BK4599","LU1093756325.SGD","IE00BKVL7J92.USD","NVO","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","BK4588"],"gpt_icon":1},{"id":"2531213559","title":"安進4月28日成交額為5.89億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531213559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531213559?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 09:15","pubTimestamp":1745889357,"startTime":"0","endTime":"0","summary":"美东时间2025年4月28日，安进成交额为5.89亿美元，成交额较昨日增加5.29%，当日成交量为208.25万股。安进于2025年4月28日涨0.8%，报283.09美元，该股过去5个交易日涨3.44%，年初至今涨9.49%，过去60日涨0.48%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429091607a46b3b5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429091607a46b3b5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","IE00BFTCPJ56.SGD","BK4588","LU0122379950.USD","IE0002141913.USD","BK4581","BK4566","LU1057294990.SGD","IE0009355771.USD","LU2468319806.SGD","LU1061106388.HKD","LU2242652126.USD","LU0868494617.USD","IE00B2B36J28.USD","LU0320765992.SGD","BK4139","BK4585","BK4533","AMGN","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0058720904.USD","LU2089984988.USD","LU0889565916.HKD","LU2242646821.SGD","LU0289739699.SGD","LU1983299246.USD","LU2112291526.USD","BK4599","LU0109394709.USD","IE00BJT1NW94.SGD","LU1571399168.USD"],"gpt_icon":0},{"id":"2531253847","title":"歐股“十一羅漢”收盤播報｜諾和諾德收漲將近2.7%，阿斯麥則跌超0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531253847","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531253847?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 01:15","pubTimestamp":1745860542,"startTime":"0","endTime":"0","summary":"周一，阿斯麦控股荷兰阿姆斯特丹股价收跌0.75%，报584.50欧元。诺和诺德哥本哈根股价收涨2.68%，报414.30。德国思爱普Sap、葛兰素史克、欧莱雅、罗氏制药、阿斯利康、雀巢涨1.68%-1.18%，诺华、赛诺菲、LVMH集团至多涨0.93%。在欧洲奢侈品概念股中，博柏利、雨果博斯、开云集团涨2.94%-2.29%。在意大利银行股中，Banca Sistema SpA.涨6.2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042901181294e62c08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042901181294e62c08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BD6J9T35.USD","03165","LU1093756168.USD","LU1734074674.USD","LU2063271972.USD","LU0823434740.USD","BK4543","ASML","IE00BZ1G4Q59.USD","LU0097036916.USD","LU0345774631.USD","NVO","BK4585","LU0823434583.USD","LU0154236417.USD","BK4007","LU0345774391.USD","IE00BKVL7J92.USD","BK4599","LU1093756325.SGD","BK4532","BK4588","BK4147","IE0004445239.USD"],"gpt_icon":0},{"id":"2530228954","title":"Viking Therapeutics, Inc.盤中異動 急速上漲5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530228954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530228954?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 21:43","pubTimestamp":1745847819,"startTime":"0","endTime":"0","summary":"北京时间2025年04月28日21时43分，Viking Therapeutics, Inc.股票出现波动，股价大幅拉升5.04%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.78%。其相关个股中，Galmed Pharmaceuticals Ltd.、Cg Oncology, Inc.、Portage Biotech Inc.涨幅较大，Galmed Pharmaceuticals Ltd.、Portage Biotech Inc.、Tharimmune, Inc.较为活跃，换手率分别为1597.19%、344.10%、66.30%，振幅较大的相关个股有Galmed Pharmaceuticals Ltd.、Protara Therapeutics, Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为27.39%、22.69%、22.50%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428214340a6cbc313&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428214340a6cbc313&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","VKTX","BK4599","BK4139","LENZ","BK4585"],"gpt_icon":0},{"id":"2530242608","title":"諾和諾德肥胖症藥物 Wegovy 首次在泰國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2530242608","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530242608?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 17:01","pubTimestamp":1745830918,"startTime":"0","endTime":"0","summary":"路透曼谷4月28日 - 丹麦诺和诺德NOVOb.CO公司当地子公司的一位高管周一表示，该公司已在泰国推出了大受欢迎的减肥药Wegovy，这标志着该注射药物首次进入东南亚市场。Bruland拒绝透露Wegovy在泰国的定价细节，也拒绝透露诺和诺德进军其他东南亚市场的计划。Bruland说，Wegovy目前在泰国各地的私立医院有处方药出售，不久将在公立医院上市。诺和诺德的糖尿病药物 Ozempic 与 Wegovy 的活性成分相同，已经在泰国上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4S3R60O2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","IE00BK4W5M84.HKD","LU2471134879.HKD","LU0109391861.USD","BK4581","BK4007","LU1983299246.USD","LU2491050071.SGD","SG9999015986.USD","LU0672654240.SGD","SGXZ51526630.SGD","LU1623119135.USD","SG9999014914.USD","IE0004445239.USD","LU1804176565.USD","LU2112291526.USD","LU2471134952.CNY","BK4534","LU0823416689.USD","IE00B2B36J28.USD","BK4588","LU0203202063.USD","LU1551013342.USD","SG9999015952.SGD","LU0058720904.USD","LU1988902786.USD","LU0943347566.SGD","LU1023059063.AUD","SGXZ99366536.SGD","LU0256863811.USD","LU1712237335.SGD","LU2237443549.SGD","SG9999015978.USD","IE00BJT1NW94.SGD","LU2106854487.HKD","LU2264538146.SGD","LU2063271972.USD","LU1868836591.USD","LU0097036916.USD","BK4599","LU0456855351.SGD","LU0203201768.USD","LU0640476718.USD","LU1127390331.HKD","LU0882574055.USD","LU0198837287.USD","LU2491049909.HKD","LU2461242641.AUD","LU1069344957.HKD"],"gpt_icon":1},{"id":"2530497866","title":"諾納生物合作伙伴輝瑞在2025 AACR年會上公佈基於TOP1i靶向人間皮素ADC療法的臨牀前數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2530497866","media":"医药魔方","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530497866?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 08:31","pubTimestamp":1745800285,"startTime":"0","endTime":"0","summary":"诺纳生物，一家致力于前沿技术创新，并为合作伙伴提供涵盖靶点验证和新一代生物大分子药物从发现至临床前研发等Idea to IND完整服务的国际化创新生物技术公司，今日宣布其合作伙伴辉瑞在2025年美国癌症研究协会年会上公布了同类首创基于拓扑异构酶1抑制剂的靶向人间皮素抗体偶联药物PF-08052666的临床前数据。2023年12月14日，辉瑞获得了其全球临床开发和商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428102605a469cf3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428102605a469cf3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0306807586.USD","BK4592","LU0058720904.USD","LU1894683348.USD","LU0122379950.USD","LU0234572021.USD","LU1066053197.SGD","LU1023059063.AUD","SG9999001176.SGD","SGXZ57979304.SGD","LU1066051498.USD","SG9999002224.SGD","SG9999002232.USD","BK4080","IE00BLSP4452.SGD","SG9999013999.USD","LU0985481810.HKD","LU0225771236.USD","BK4568","PFE","BK4581","LU1057294990.SGD","IE0002270589.USD","SG9999001176.USD","BK4585","LU0170899867.USD","IE00BBT3K403.USD","LU1883839398.USD","IE00B19Z3581.USD","BK4007","LU0225284248.USD","LU0289739699.SGD","BK4588","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","IE00BLSP4239.USD","LU0321505868.SGD","SG9999003800.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999011175.SGD","BK4550","BK4533","BK4231","LU1894683264.USD","IE000M9KFDE8.USD","ADC","BK4534","BK4599"],"gpt_icon":1},{"id":"2530454984","title":"安進宣佈投資9億美元擴建俄亥俄州生產基地，新增350個工作崗位","url":"https://stock-news.laohu8.com/highlight/detail?id=2530454984","media":"药事纵横","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530454984?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 00:03","pubTimestamp":1745769792,"startTime":"0","endTime":"0","summary":"2025年4月25日，安进公司对外宣布，该公司将对其俄亥俄州生产基地追加9亿美元投资，使该州累计新增就业岗位达750个，在中俄亥俄州总投资额超过14亿美元。此次投资进一步彰显我们对扩大美国生产基地的承诺，确保全球患者能持续获得创新药物。\"安进于2021年6月首次进驻俄亥俄州，宣布在中俄亥俄州建设尖端生物制药基地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428002754a4695b56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428002754a4695b56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B4R5TH58.HKD","BK4139","AMGN","IE0002141913.USD","IE00B2B36J28.USD","LU2242652126.USD","BK4599","BK4534","BK4566","LU1061106388.HKD","LU2089984988.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4533","LU1057294990.SGD","LU0868494617.USD","BK4588","LU2112291526.USD","LU1983299246.USD","BK4585","LU0122379950.USD","LU0889565916.HKD","LU2468319806.SGD","LU2242646821.SGD","BK4581","LU1571399168.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","SG9999001440.SGD","LU0320765992.SGD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2530193102","title":"安進擬斥9億美元擴建美國俄亥俄州工廠","url":"https://stock-news.laohu8.com/highlight/detail?id=2530193102","media":"格隆汇APP","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530193102?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 11:08","pubTimestamp":1745723280,"startTime":"0","endTime":"0","summary":"格隆汇4月27日｜制药公司安进周五表示，将投资9亿美元扩建美国俄亥俄州的制造工厂，料增加350个工作岗位。去年12月，安进宣布斥资10亿美元在北卡罗来纳州霍利斯普林斯建造第二间原料药厂。               \n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-04-27/doc-ineuqqcx0040528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1023059063.AUD","LU0058720904.USD","BK4533","LU2089984988.USD","IE0002141913.USD","LU2112291526.USD","BK4139","SG9999001440.SGD","LU0122379950.USD","LU2242646821.SGD","AMGN","BK4588","LU0320765992.SGD","IE00B2B36J28.USD","BK4585","IE00B4R5TH58.HKD","LU0109394709.USD","LU1061106388.HKD","IE00BJT1NW94.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","BK4566","BK4534","LU2242652126.USD","BK4581","BK4599","LU0289739699.SGD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0889565916.HKD","LU1057294990.SGD","LU1983299246.USD"],"gpt_icon":0},{"id":"2530279141","title":"數百億美元！艾伯維、默沙東、安進紛紛宣佈投資美國","url":"https://stock-news.laohu8.com/highlight/detail?id=2530279141","media":"Medaverse","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530279141?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 20:44","pubTimestamp":1745671472,"startTime":"0","endTime":"0","summary":"4月25日，由于药品进口关税可能会刺激美国对生命科学的投资热潮，艾伯维也加入了这一趋势，计划在未来十年内在美国投资100亿美元。在此之前，诺华、礼来和强生已作出重大承诺，将扩大其在美国的足迹，并公布了230亿至550亿美元的投资。艾伯维报告称2025年第一季度收入为133.4亿美元，同比增长8.4%。Rinvoq也表现良好，销售额增长57%，达到17亿美元。Humira目前仅占AbbVie总收入的8%，环比下降3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426234320a6c96fda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426234320a6c96fda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1037948541.HKD","LU2242652126.USD","LU0320765489.SGD","LU2112291526.USD","SG9999014567.USD","LU1093756325.SGD","LU0211331839.USD","LU0109394709.USD","LU2023250843.SGD","LU2089984988.USD","AMGN","LU1035773651.USD","LU1061106388.HKD","SG9999015358.SGD","IE00BN8TJ469.HKD","LU1941712264.USD","LU0985320562.USD","LU0238689110.USD","IE00BJT1NW94.SGD","BK4588","LU1989772840.SGD","IE00BLSP4452.SGD","LU1162221912.USD","LU1934455277.USD","LU0266013472.USD","BK4007","LU2361044949.HKD","LU1917777945.USD","BK4599","BK4533","LU0965508806.USD","BK4516","SG9999002224.SGD","LU1934455194.USD","LU1974910355.USD","LU1983299246.USD","SG9999013999.USD","IE00BJJMRZ35.SGD","MRK","LU1585245621.USD","LU1116320737.USD","LU2242646821.SGD","ABBV","LU1066051811.HKD","SGXZ57979304.SGD","LU0965509101.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","LU0203345920.USD","LU2361045086.USD","LU0203347892.USD"],"gpt_icon":0},{"id":"2530772119","title":"輝瑞4月25日成交額為8.20億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530772119","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530772119?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 10:18","pubTimestamp":1745633897,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，辉瑞成交额为8.20亿美元，成交额较昨日增加3.34%，当日成交量为3584.77万股。辉瑞于2025年4月25日涨0.61%，报22.92美元，该股过去5个交易日涨3.52%，年初至今跌12.18%，过去60日跌13.9%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-25|8.20亿|3.34%|3584.77万|#|2025-04-24|7.94亿|-30.67%|3500.96万|#|2025-04-23|11.45亿|41.51%|5078.10万|#|2025-04-22|8.09亿|14.76%|3605.26万|#|2025-04-21|7.05亿|-41.56%|3202.10万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101825a46793a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101825a46793a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","BK4588","LU0122379950.USD","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","LU1023059063.AUD","LU0058720904.USD","BK4592","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2530119984","title":"諾和諾德4月25日成交額為4.83億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530119984","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530119984?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 10:12","pubTimestamp":1745633543,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，诺和诺德成交额为4.83亿美元，成交额较昨日减少1.84%，当日成交量为783.52万股。诺和诺德于2025年4月25日跌0.88%，报62.08美元，该股过去5个交易日涨6.89%，年初至今跌26.86%，过去60日跌25.1%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-25|4.83亿|-1.84%|783.52万|#|2025-04-24|4.92亿|-12.38%|789.11万|#|2025-04-23|5.62亿|-19.53%|912.87万|#|2025-04-22|6.98亿|-10.34%|1169.79万|#|2025-04-21|7.79亿|-58.42%|1341.93万|诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101230a4679296&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101230a4679296&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4585","LU0154236417.USD","BK4588","BK4599","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756325.SGD","LU1093756168.USD","BK4007"],"gpt_icon":1},{"id":"2530113678","title":"安進4月25日成交額為5.59億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530113678","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530113678?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 09:15","pubTimestamp":1745630151,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，安进成交额为5.59亿美元，成交额较昨日减少11.47%，当日成交量为199.46万股。安进于2025年4月25日涨0.36%，报280.84美元，该股过去5个交易日涨1.28%，年初至今涨8.62%，过去60日涨0.51%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426091609a4678431&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426091609a4678431&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0058720904.USD","BK4139","IE00BJT1NW94.SGD","LU1023059063.AUD","LU1571399168.USD","LU1061106388.HKD","LU0289739699.SGD","BK4581","LU2242646821.SGD","LU0109394709.USD","BK4566","BK4534","BK4585","AMGN","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU2242652126.USD","IE0009355771.USD","LU1057294990.SGD","LU0889565916.HKD","LU2089984988.USD","BK4599","LU0122379950.USD","LU1983299246.USD","LU0868494617.USD","IE0002141913.USD","LU2112291526.USD","LU0320765992.SGD","SG9999001440.SGD","LU2468319806.SGD","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","BK4588"],"gpt_icon":0},{"id":"2530679461","title":"禮來盤中異動 股價大漲3.00%報885.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530679461","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530679461?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 03:54","pubTimestamp":1745610851,"startTime":"0","endTime":"0","summary":"北京时间2025年04月26日03时54分，礼来股票出现异动，股价大幅上涨3.00%。截至发稿，该股报885.49美元/股，成交量257.896万股，换手率0.29%，振幅3.89%。最近的财报数据显示，该股实现营业收入450.43亿美元，净利润105.90亿美元，每股收益11.76美元，毛利366.24亿美元，市盈率75.53倍。礼来股票所在的制药行业中，整体涨幅为1.60%。消息层面，截至03时54分，《迎战礼来，诺和诺德抢先递交口服 GLP-1减重上市申请》资讯为影响礼来的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042603541194e2e38d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042603541194e2e38d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0256863902.USD","LU1057294990.SGD","SG9999015952.SGD","IE0002141913.USD","LU0354030511.USD","LU1804176565.USD","SG9999018857.SGD","LU2023250504.SGD","LU2750360641.GBP","LU2461242641.AUD","LU2471134523.USD","SG9999017495.SGD","SG9999015978.USD","GB00BDT5M118.USD","IE00BK4W5L77.USD","LU1720051017.SGD","SG9999001176.SGD","LU0708995401.HKD","LU1064131342.USD","LU2106854487.HKD","LU2237443549.SGD","LU0238689110.USD","LU0820561909.HKD","LU0820561818.USD","SG9999014898.SGD","LU0006306889.USD","LU2471134796.USD","IE00BK4W5M84.HKD","SGXZ81514606.USD","LU2750360997.AUD","SG9999014880.SGD","LU1917777945.USD","IE00BJJMRZ35.SGD","SGXZ57979304.SGD","LU0256863811.USD","LU1720051108.HKD","LU1814569148.SGD","BK4599","LU2264538146.SGD","SGXZ99366536.SGD","IE00BJT1NW94.SGD","LLY","LU1548497426.USD","LU1069344957.HKD","LU0471298694.HKD","LU2089984988.USD","BK4588","LU0106261372.USD","IE00B1BXHZ80.USD","LU0417517546.SGD"],"gpt_icon":1},{"id":"2530153458","title":"諾和諾德贏得重大法律勝利，眾多Wegovy和Ozempic的調配版藥物被禁售","url":"https://stock-news.laohu8.com/highlight/detail?id=2530153458","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530153458?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 23:01","pubTimestamp":1745593311,"startTime":"0","endTime":"0","summary":"要点诺和诺德赢得了一场重大的法律胜利，这在很大程度上限制了调配药房推销或销售该制药公司的畅销减肥药维格威和糖尿病治疗药物奥泽美的更便宜、未经批准的版本。周四的这一决定是继诺和诺德的另一场胜利之后做出的。今年 3 月，一名联邦法官驳回了调配行业组织提出的关于美国食品药品监督管理局对其成员仿制莫诺拉和泽普邦采取执法行动的初步禁令请求。该调配行业组织已提出上诉。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042523060694e29da3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042523060694e29da3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4588","IE00BKVL7J92.USD","LU1093756168.USD","BK4007","BK4585","BK4599"],"gpt_icon":1},{"id":"2530137224","title":"禮來公司請求歐洲藥品管理局重新審查阿爾茨海默氏症藥物建議","url":"https://stock-news.laohu8.com/highlight/detail?id=2530137224","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530137224?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 22:30","pubTimestamp":1745591400,"startTime":"0","endTime":"0","summary":"更新版 1-礼来公司请求欧洲药品管理局重新审查阿尔茨海默氏症药物建议在第3、4和5段中增加了详细信息。路透4月25日 - 礼来LLY.N周五表示，已要求欧洲药品监管机构重新审查其对该公司阿尔茨海默氏症药物的意见。上个月，监管机构否决了该药Kisunla，称其减缓认知能力衰退的能力不足以抵消患者脑部严重肿胀的风险。礼来公司当时曾表示， ，计划向监管机构申请复审。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4T3R31JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU0203202063.USD","LU1093756168.USD","SG9999018865.SGD","LU0061475181.USD","LU1064131342.USD","LU2237443465.HKD","LU2357305700.SGD","LU2602419157.SGD","SGXZ81514606.USD","LU0882574055.USD","LU2106854487.HKD","SG9999015978.USD","LU0882574139.USD","SG9999014906.USD","LU0689472784.USD","LU2471134523.USD","LU1720051108.HKD","SG9999015986.USD","SG9999015945.SGD","LU0106261372.USD","BK4533","LU1232071149.USD","LLY","LU1989771016.USD","LU2237443382.USD","LU2211815571.USD","LU0320765059.SGD","LU1623119135.USD","LU0471298694.HKD","LU1868837300.USD","LU0289739699.SGD","LU0114720955.EUR","LU0198837287.USD","LU0256863811.USD","BK4599","LU1127390331.HKD","LU2264538146.SGD","LU2237443895.HKD","LU0456855351.SGD","LU1868836591.USD","BK4581","LU1280957306.USD","LU2552382215.SGD","LU0109391861.USD","SG9999014898.SGD","IE0009355771.USD","LU2361044865.SGD","LU2360106947.USD","LU0354030511.USD"],"gpt_icon":0},{"id":"2530586241","title":"諾和諾德贏得重大法律勝利：多款司美格魯肽和諾和泰的配製版藥物被禁售","url":"https://stock-news.laohu8.com/highlight/detail?id=2530586241","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530586241?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 22:28","pubTimestamp":1745591301,"startTime":"0","endTime":"0","summary":"查看最新行情诺和诺德取得了一场重大的法律胜利，这在很大程度上限制了配制药店营销或销售该制药商的畅销减肥药司美格鲁肽和糖尿病治疗药物诺和泰的更便宜且未经批准的仿制版本。当地时间周四晚些时候，得克萨斯州的一名联邦法官驳回了配制药店的一项请求，该请求试图在针对这些药物短缺的法律质疑仍在进行期间，继续生产诺和泰和司美格鲁肽的仿制版药物。该配制药品行业组织已提出上诉。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042522295094e2960d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042522295094e2960d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4007","BK4599","LU1093756325.SGD","NVO","IE00BKVL7J92.USD","BK4585","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4532","BK4588"],"gpt_icon":1},{"id":"2530132873","title":"Viking Therapeutics, Inc.盤中異動 早盤大幅下挫5.03%報24.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530132873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530132873?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 21:55","pubTimestamp":1745589310,"startTime":"0","endTime":"0","summary":"北京时间2025年04月25日21时55分，Viking Therapeutics, Inc.股票出现波动，股价快速下挫5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.16%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。该信息摘要如下：大摩：维持Viking Therapeutics评级，由增持调整至增持评级, 目标价由105.00美元调整至102.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425215510a466e83e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425215510a466e83e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LENZ","VKTX","BK4007","BK4599","BK4139","BK4585"],"gpt_icon":0},{"id":"2530131602","title":"諾和諾德盤中異動 早盤快速下挫2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530131602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530131602?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 21:31","pubTimestamp":1745587882,"startTime":"0","endTime":"0","summary":"北京时间2025年04月25日21时31分，诺和诺德股票出现波动，股价大幅跳水2.92%。诺和诺德股票所在的制药行业中，整体跌幅为0.18%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。该信息摘要如下：自2021年推出广受欢迎的减肥药Wegovy以来，诺和诺德每年多次上调年度销售指引。诺和诺德2月曾表示，其已增加Wegovy在美国的供应以满足激增需求，并称指引已反映这一调整。诺和诺德称，该禁令可能将需求转向其正版产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213122a6c81ce2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213122a6c81ce2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4588","IE00BKVL7J92.USD","LU1093756168.USD","BK4007","BK4585","BK4599","NVO"],"gpt_icon":1}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":122,"code":"91000000","status":"200"}]}}